Prof. Scherre Didier
Didier, prior to joining ABIVAX, combined the functions of CEO and Scientific Directory at Splicos. Didier has a PhD in Molecular Pharmacology. He completed his post-doctoral studies at Harvard Medical School and then at the Stanford University School of Medicine. Research Director at Entelos (California – USA) from 2000 to 2005, he then joined the Research Department of Astra-Zeneca as Associate Director (Capability Pathways – Discovery Enabling Capabilities and Sciences), and then as Head of Research, at LFB Biotechnologies where he led a team of fifty scientists in charge of developing the portfolio of therapeutic proteins in oncology, autoimmune diseases and hematology-oncology. He is the author of numerous publications and presentations in the field of systems biology applied to the research and drug development.
therapeutic proteins in oncology, autoimmune diseases and hematology-oncology.